Age

50–any

Sex

ALL

Healthy volunteers

Accepted

Males or females ≥ 50 years of age at time of consent
≥ 4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (14, 15)
Clinically stable SLE
Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks
Corticosteroid use: ≥ 5mg/day of prednisolone equivalent
Antimalarials (≤ 400 mg/day)
Azathioprine (≤ 3 mg/kg/day)
Mycophenolate mofetil (≤ 3 mg/day)
Tacrolimus (≤ 5mg/day)
Methotrexate (≤ 20mg/week)
Cyclosphosphamide (≤ 1mg/BSA/month)
Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine
Must understand and voluntarily sign an informed consent form including writing consent for data protection

Pregnant or lactating females
Acute infection with temperature \>38C at the time of vaccination
Previous anaphylactic response to vaccine components or to egg
History of Guillain-Barre syndrome or demyelinating syndromes
Any condition including laboratory abnormality which places the subject at unacceptable risk
Subjects who decline to participate

Reduced Vaccine Response to HZ/su in SLE